Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU warns not enough COVID vaccines for all in Europe until 2022

10/27/2020 | 11:36am EDT
FILE PHOTO: A woman holds a small bottle labeled with a

BRUSSELS (Reuters) - Only part of the European Union population can be inoculated against the new coronavirus before 2022, EU officials said in an internal meeting, as the vaccines the bloc is securing may not prove effective or may not be manufactured in sufficient doses.

The 27-nation bloc, with a population of 450 million, has booked more than 1 billion doses of potential COVID-19 vaccines from three drugmakers. It is negotiating the advance purchase of another billion vials with other companies.

"There will not be sufficient doses of COVID-19 vaccines for the entire population before the end of 2021," a European Commission official told diplomats from EU states in a closed-door meeting on Monday, a person who attended it told Reuters.

A second official confirmed the statement. An EU Commission spokesman was not immediately available for comment.

The EU Commission had earlier said vaccines will be limited "during the initial stages of deployment" but had never clarified how long the initial phase would last.

There is still no effective COVID-19 vaccine, but the first shots could be available at the beginning of next year, the Commission said earlier in October.

Given a likely limited supply, the Commission has for months urged EU governments to devise vaccination plans that would prioritise vulnerable and essential groups, such as healthcare workers, the elderly or people with chronic diseases.

But apart from a consensus on inoculating doctors and nurses, "there is no common line on other groups," the Commission official said at the internal meeting this week.

In July a paper agreed by the Commission and EU governments said at least 40% of the EU population should be vaccinated in the first phase.

Some EU countries want to book doses for their entire population with the aim of rolling them out already by mid-2021.

A third EU official said this bold goal could be achieved if the EU reached supply deals with at least seven vaccine candidates.

The EU has so far secured doses of the potential vaccines being developed by AstraZeneca, Sanofi and Johnson & Johnson. It has also said it is in talks with Moderna, Pfizer and CureVac.

(Reporting by Francesco Guarascio @fraguarascio, Editing by William Maclean and Alexandra Hudson)

By Francesco Guarascio

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.27% 7380 Delayed Quote.0.76%
MODERNA, INC. 6.84% 170.81 Delayed Quote.53.03%
PFIZER INC. 2.58% 38.57 Delayed Quote.2.15%
SANOFI 0.47% 85.01 Real-time Quote.8.02%
All news about ASTRAZENECA PLC
03:35pJ&J Covid-19 Vaccine Was Paused Over Blood-Clot Treatment Concerns -- 2nd Upd..
03:03pJ&J Covid-19 Vaccine Was Paused Over Blood-Clot Treatment Concerns -- Update
06:14aCOVID-19 VACCINES AND RARE BLOOD CLO : Are Women at Greater Risk?
04/17ASTRAZENECA  : Canada has second case of rare blood clots after AstraZeneca vacc..
04/17ASTRAZENECA  : Canada has second case of rare blood clots after AstraZeneca COVI..
04/17U.S. PARENTS BEGIN TO ASK : Should my child get a COVID-19 shot?
04/17ASTRAZENECA  : Alberta confirms country's second blood clot after AstraZeneca va..
04/17ASTRAZENECA  : Covid-19 Vaccine - No Diagnosed Case of Blood Clots, No Death Rec..
04/17ASTRAZENECA  : Covid-19 - Nigeria Crosses 1 Million Vaccination Threshold
04/17MODERNA  : vaccine shipments to the UK delayed over supply chain concerns
More news
Financials (USD)
Sales 2021 30 793 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.09%427 130
ROCHE HOLDING AG0.06%289 376
PFIZER INC.2.15%215 150
NOVARTIS AG-3.32%198 528
MERCK & CO., INC.-5.29%196 100